Open Access<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>
Author(s) -
Yuzo Suzuki,
Naoki Inui,
Masato Karayama,
Shiro Imokawa,
Takashi Yamada,
Koushi Yokomura,
Kazuhiro Asada,
Hideki Kusagaya,
Yusuke Kaida,
Hiroyuki Matsuda,
Naoki Koshimizu,
Mikio Toyoshima,
Masafumi Masuda,
Hiroshi Hayakawa,
Hironao Hozumi,
Kazuki Furuhashi,
Noriyuki Enomoto,
Tomoyuki Fujisawa,
Takafumi Suda
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s214610
Subject(s) - medicine , copd , exhaled nitric oxide , exacerbation , nivolumab , lung cancer , pulmonary function testing , gastroenterology , lung , cancer , lung function , immunotherapy
Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor, has been shown to improve survival in non-small cell lung cancer (NSCLC). The possible involvement of PD-1 axis in the pathogenesis of inflammatory lung disease, such as chronic obstructive pulmonary disease (COPD) has also been reported. However, effects of PD-1 blockade on the respiratory system remain unknown.